Sat, Apr 19, 2014, 3:25 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Anthera Pharmaceuticals, Inc. (ANTH) Message Board

  • mm_hf_14 mm_hf_14 Dec 5, 2012 7:18 PM Flag

    Good reason to buy and be patient

    Anthera Pharmaceuticals Inc. (ANTH) is a company with a market cap below $100M and plenty of cash. It is ready to go into phase 3 trials with a B-cell molecule product [A-623]. Yet the company appears to be misunderstood by the market.

    Anthera's B-cell molecule product, targeting lupus, appears to be an improvement over GlaxoSmithKline's (GSK) Benlysta [belimumab]. Anthera's phase 2 dose-ranging data was complicated and lacked statistical significance. However, the company found that the drug candidate is very active in sicker patients. Anthera has designed the clinical trials and obtained sign-off from both the FDA and the European regulatory authorities to start phase 3 late this year or early next year. We should get some additional data at the American College of Rheumatology [ACR] meeting in November.

    The phase 3 trials, the ACR meeting and a good management team provide excellent catalysts in the coming months.

    Sentiment: Strong Buy

2.87-0.01(-0.35%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT